Head and neck squamous cell carcinoma
Conditions
Interventions
In the patients with distant metastasis, intra-venous and sub-mucosal injections of alpha-GalactosylCeramide pulsed DCs are performed at 1, 2, 7 and 8 weeks after the entry. In the patients with loca
Sponsors
Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Head and neck squamous cell carcinoma patients who have measurable lesion Patients whose life-expectancy is more than 6 months Performance status 0-1 Normal bone marrow, liver and renal functions NKT cells are detected at least 10 cells in 1 mL of peripheral blood and expanded more than 100 times in vitro.
Exclusion criteria
Exclusion criteria: Patients who have: been treated with previous therapy of at least 4 weeks; uncontrolled diabetes mellitus, interstitial pneumonia, pleural effusion, ascites and/or pericardial effusion; a history of hepatitis; a positive response for hepatitis B surface antigen, or human immunodeficiency virus (HIV), hepatitis C virus, or human T-lymphotrophic virus antibodies; other cancers; serious cardiac disease; recieived concurrent corticosteroid therapy; pregnancy or lactation; autoimmune diseases; been judged to be inappropriate to participate in this study by principle investigator or co-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunological response | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety, Clinical response | — |
Countries
Japan
Outcome results
None listed